2023-05-26 12:04:42 ET
- Elevation Oncology ( NASDAQ: ELEV ) is up 61% in Friday trading after release promising phase 1 data from a dose-escalation study on a solid tumors antibody-drug conjugate.
- The candidate, SYSA1801, targets the Claudin18.2 protein, which is seen in many types of tumors.
- At total of 33 patients with either gastric cancer or pancreatic cancer were enrolled. Twenty-one were evaluable for efficacy.
- Results showed that the objective response rate was 38.1% and disease control rate 57.1%. Among the 17 evaluable patients with gastric cancer, the figures were, respectively, 47.1% and 64.7%.
- Grade 3 or higher adverse events were seen in eight of the 33 people in the trial.
- The study was conducted in China , with part 2 of the phase 1 trial to begin when an optimal dose is determined. The company said it anticipates starting a phase 1 trial in the US this year.
For further details see:
Elevation Oncology up 61% on early-stage data for gastric cancer treatment